These markers also displayed significant differences between NSCLC stages III-IV patients and controls (p = 0.012 for EGF and p<0.001 for CAL), in spite of EGF displaying notable inferior levels in advanced stages as compared to earlier stages. The gene discussed is EGF; the disease is non-small cell lung carcinoma.